Reshaped human MAb RSHZ19, which is specific for the surface fusion protein of respiratory syncytial virus (RSV) is in clinical development for the prevention and treatment of RSVinduced disease in human infants. The current studies profile lung virus clearance and evaluate lung histopathology in MAbtreated, RSV-infected cotton rats, a well characterized model of RSV infection. The highest dose of this MAb (10 m a g ) administered parenterally 24 h before infection decreased subgroup A or B RSV lung titers to below detectable levels (22.3 log,, reduction), and significantly reduced lung virus titers (22.0 log,, reduction) when administered 96 h postinfection. Prophylactic administration of 10 mgkg RSHZ19 was significantly more protective than 1000 m a g conventional human immune serum globulin (HSIg), and protective serum-neutralizing titers in MAb-treated animals (1:32, which correlated with approximately 40 pg/ml determined by anti-idiotype ELISA) were significantly lower than those reported previously for HSIg or for convalescent human serum (1:200-1:400). MAb concentration in lung lavages was determined by ELISA to be approximately 1% of the serum MAb concentration, but was not detectable by neutralization assay. The degree of lung histopathology in MAb-treated cotton rats was proportional to lung virus titer, and inversely proportional to the RSHZ19 dose administered. There was no evidence of exacerbated disease in the lungs of MAb-treated animals. These studies thus support the potential clinical utility of RSHZ19 MAb in the prevention and treatment of RSVinduced disease in humans. (Pediatr Res 38: 543-550, 1995) Abbreviations RSV, respiratory syncytial virus HSIg, human serum Ig FI, fusion inhibition TCID,,, tissue culture 50% infectious dose F protein, fusion protein RSV is a leading cause of serious lower respiratory tract infection in infants and children under 2 y of age (1). No vaccines are currently available for prevention of RSV infections, and the only antiviral available to treat RSV disease, ribavirin, is restricted to use in high risk or severely ill infants (2). Because it is routinely administered as a continuous small particle aerosol (usually over a period of days) and is a potential teratogen, the utilization of ribavirin has been both limited and somewhat controversial (3).
Reshaped human MAb RSHZ19, which is specific for the surface fusion protein of respiratory syncytial virus (RSV) is in clinical development for the prevention and treatment of RSVinduced disease in human infants. The current studies profile lung virus clearance and evaluate lung histopathology in MAbtreated, RSV-infected cotton rats, a well characterized model of RSV infection. The highest dose of this MAb (10 m a g ) administered parenterally 24 h before infection decreased subgroup A or B RSV lung titers to below detectable levels (22.3 log,, reduction), and significantly reduced lung virus titers (22.0 log,, reduction) when administered 96 h postinfection. Prophylactic administration of 10 mgkg RSHZ19 was significantly more protective than 1000 m a g conventional human immune serum globulin (HSIg), and protective serum-neutralizing titers in MAb-treated animals (1:32, which correlated with approximately 40 pg/ml determined by anti-idiotype ELISA) were significantly lower than those reported previously for HSIg or for convalescent human serum (1:200-1:400). MAb concentration in lung lavages was determined by ELISA to be approximately 1% of the serum MAb concentration, but was not detectable by neutralization assay. The degree of lung histopathology in MAb-treated cotton rats was proportional to lung virus titer, and inversely proportional to the RSHZ19 dose administered. There was no evidence of exacerbated disease in the lungs of MAb-treated animals. These studies thus support the potential clinical utility of RSHZ19 MAb in the prevention and treatment of RSVinduced disease in humans. (Pediatr Res 38: 543-550, 1995) Abbreviations RSV, respiratory syncytial virus HSIg, human serum Ig FI, fusion inhibition TCID,,, tissue culture 50% infectious dose F protein, fusion protein RSV is a leading cause of serious lower respiratory tract infection in infants and children under 2 y of age (1) . No vaccines are currently available for prevention of RSV infections, and the only antiviral available to treat RSV disease, ribavirin, is restricted to use in high risk or severely ill infants (2) . Because it is routinely administered as a continuous small particle aerosol (usually over a period of days) and is a potential teratogen, the utilization of ribavirin has been both limited and somewhat controversial (3) .
A number of studies in animals (4) (5) (6) (7) (8) and more recently in children (9-ll), indicate that HSIg selected for high neutralizing titers to RSV may be useful as an alternative or complementary approach to ribavirin and RSV vaccines in the prevention and treatment of these infections. However, the clinical data from a prophylaxis trial indicate that even pooled RSV immune globulin (RSV Ig) preparations selected for high anti-RSV neutralizing titers must be administered at very high doses (750 mg/kg) to achieve significant protective effects (10) .
MAb with' RSV neutralizing activity might be superior to pooled immune globulin preparations in terms of uniform specificity and improved potency. Numerous RSV-specific murine MAb have been described, but the potential for immunoeenicitv and subo~timal half-life mav limit the utility of hypervariable complementarity determining regions into hu-544 WYDE man variable framework regions which are expressed with human heavy and light chain constant regions to produce intact IgG molecules (13) . In this way, the specificity and biologic activity characteristic of a murine MAb can be retained in a human IgG structure.
RSHZ19 is a reshaped human MAb (1gG1,~) which is specific for the F protein of RSV (14) (RSHZ19 is described as HuRSV19VHFNS/VK in Ref. 14.) This MAb, which had been shown previously to protect Balblc mice from subgroup A RSV infection (14, 15) is currently being evaluated in human clinical trials (16) . The parent murine MAb (MAb 19), which was generated by inoculating Balb/c mice intranasally with the A2 RSV strain, was shown to have potent fusion-inhibiting activity, and to bind to a panel of subgroup A and B isolates (14, 15) . The current studies were performed in the cotton rat, a well established model of RSV infection, to evaluate: 1 ) the spectrum of activity of RSHZ19 versus subgroup A and B RSV strains, 2) the potency of RSHZl9 for lung virus clearance, 3) protective circulating antibody titers and direct comparison to polyclonal HSIg administered comparably, and 4) the potential for pulmonary histopathology. The data obtained indicate that potency relative to conventional HSIg is improved at least 100-fold, and that lung virus replication and lung histopathology in subgroup A-or B-infected animals is inversely correlated with the dose of MAb administered.
METHODS

Animals.
All cotton rats (Sigmodon hispidus) used in these studies were descendants of two pair of animals obtained in 1984 from the Small Animal Section of the Veterinary Research Branch, Division of Research Services, National Institutes of Health. Test animals were between 60 and 110 g at the start of each experiment, and of either sex. All animals were maintained in cages with barrier filters, and were fed water and food ad libitum.
Tissue culture. HEp-2 cells (ATCC CCL 23) or VERO cells ( A n CCL 81) were used to grow and test for the presence of RSV. Both cell lines were originally obtained from the American Type Culture Collection (ATCC, Bethesda, MD) and serially passaged in Eagle's minimal essential medium, supplemented with 10% FCS, 100 Uslml penicillin, 100 pg/ml streptomycin sulfate, 2 mM L-glutamine, and 0.2% sodium bicarbonate whenever they became confluent. Minimal essential medium supplemented with 2% FCS was used to maintain HEp-2 cell cultures and in all virus and antibody assays. MAb. The production, reshaping, and characterization of reshaped human MAb, RSHZ19, have all been described in detail by Tempest et al. (14) . Briefly, this MAb was constructed by grafting the complimentarity determining regions from a murine MAb (MAbl9) specific for the F protein of RSV (15, 17) , into human IgG heavy and K light chain-variable domain frameworks. MAb CMHZOO, which had identical human constant and variable framework regions as RSHZ19, but which was engineered to bind human cytomegalovirus (it does not bind RSV), was used as a comparative control. The cell line expressing the CMHZOO MAb was obtained from Scotgen Biopharmaceuticals, Inc., Aberdeen, Scotland. The MAb were purified from conditioned medium using conventional protein A affinity cation exchange and gel filtration chromatography procedures. The purified antibodies appeared homogeneous after SDS-PAGE and during analytical size exclusion chromatography, resolved as single peaks with apparent molecular masses of 160 kD. Endotoxin levels in all preparations were below 1 ng/mg protein.
HSZg. The HSIg preparation used in these experiments was obtained from Armour Pharmaceuticals, Phoenix, AZ (Gammar, lot S19610); this preparation (intramuscular formulation) contained 165 mg of y-globulinlml. In microneutralization and FI antibody assays (described below) using a panel of different subtype A and B RSV viruses, the RSV-neutralizing titers of this preparation ranged from 6400 to 12,800 (EC,, range = 12.5-25 pg/ml), whereas the FI antibody titers ranged from 1240 to 2480 (EC,, range = 65-130 pglml).
Virus quantification. Serial 0.5 log,, dilutions of each test sample in 2% FCS-minimal essential medium were added to microtiter plates containing 3 X lo3 HEp-2 cells/well and incubated at 36OC (5% CO,). On d 7, the wells were scored by visual inspection (without staining) for the formation of syncytia. Calculation of endpoints were made using the method of Karber (18) . The amount of virus present in each suspension was expressed either as median TCID5,/ml, or if lung suspensions were involved, geometric mean virus titers (log,, TCID,,/g of lung). The minimum detectable virus concentration was 1.3 10g,~/g of lung.
Antibody assays. Assays for detecting and quantifying virusspecific neutralizing antibodies in sera, lung lavage fluids, or MAb suspensions were performed in duplicate in HEp-2 tissue cells in microtiter plates as described in detail elsewhere (19) . Approximately 100 TCID,, virus was used, unless otherwise noted. Antibody levels in MAb preparations were expressed as the IgG concentration that completely inhibited virus in onehalf the replicate wells (EC,,). The minimum detectable neutralizing titer in serum was 1 log,. Mean serum neutralization titers were derived from individual animals or from pooled sera from each treatment group in each experiment (three to four animalslgroup), depending on quantity of sera obtained per animal.
FI assays were performed in quadruplicate as described by Mufson et al. (20) . The FI titer was expressed as the log, of the reciprocal of the highest dilution which completely inhibited syncytia formation.
RSV PROTECTIVE RESHAPED HUMAN MAb RSHZ19 545 An anti-idiotypic ELISA was used to specifically measure all performed using True Epistat, a statistical program designed serum and lung lavage concentrations of RSHZ19. The by T. L. Gustafson of Epistat Services, Richardson, TX, for RSHZ19-specific anti-idiotypic MAb used as the capture anti-IBM-compatible computers. To determine whether RSHZ19 body in this assay was generated by immunizing calves with was equipotent against type A versus type B challenge, power the parent murine MAb (MAbl9), and will be described in calculations based on regression analysis of the dose responses detail elsewhere (Taylor G., in preparation). Bound RSHZ19 were utilized. was quantitated with peroxidase labeled anti-human IgG or with biotinylated anti-idiotypic MAb. To compare circulating RESULTS concentrations of human IgG in cotton rats treated with Antiviral activity of test MAb in vitro. The MAb used in this RSHZ19 MAb Or with HS1g7 goat anti-human IgG was used as study were tested for their ability to completely inhibit growth the capture antibody, and bound IgG was detected with perox-of a panel of different RSV subtype A and B strains in in vitro idase-labeled sheep anti-human IgG.
neutralization antibody assays ( Table 1) . As indicated by the Experimental designs. Test antibody preparations were ad-relatively low EC,, values obtained for RSHZ19 (EC,, values ministered intraperitoneally or intramuscularly as noted in the ranging from 0.4 to 3 pg proteinlml), this MAb had marked, text. Virus was always administered intranasally. For prophy-and equivalent, virus-neutralizing activity against all of the lactic studies, the cotton rats were anesthetized with Metofane, RSV strains tested, regardless of their subtype. HSIg also and with MAb (CMHZoo) Or test neutralized all RSV strains tested, but EC,, values were sigMAb (RSHZ19) 24 h before with a~~r o x i m a t e l~ loo nificantly higher than those observed with RSHZ19 ('2.5-25 TC1D5~ of subgroup A (strain A2) Or (strain 18537) RSV' pglml versus 0.4-3 pglml, respectively). In contrast, the conThe animals were killed on d 4 postinfection (at which time trol CMHZOO MAb had no significant neutralizing activity maximal RSV replication usually occurs), and serum and lung against RSV isolates of either subtype (EC,, values were >I14 lavages (3 ml) were collected as described previously (20) for pglml). The activity of the test MAb in FI assays was equivantibody and virus titrations. In some instances, nasal washes alent to that observed in the neutralization assays (i.e. the mean (21), as well as lavage fluids, were collected for virus titrations. EC5, of RSHZ19 against the different RSV stains was = 0.5 For therapeutic studies, animals were treated with test or pglml, whereas that of the CMHZOO MAb was >I30 pglml; control m b on d 4 post infection with RSV strain A2 or 18537 data not shown). FI titers of HSIg were approximate~y 5-fold and 24 later' In each three to higher than corresponding neutralization titen (65-130 , , drnl; rats per dose group were included. data not shown). In some studies, additional animals were included for histoConcentration of RSHZ19 in plasma and lung luvagejluid logic studies on d 7 postinfection when maximum virus-after intraperitoneal administration. Concentrations of induced pulmonary inflammation was expected to occur (5, 6) . RSHZ19 in plasma and lung lavage fluids from uninfected In other studies, extra uninfected animals were included to cotton rats (n = 3) at selected time points were determined determine 1) the kinetics of clearance of RSHZ19 in serum and using the anti-idiotype ELISA (Fig. 1) . Within hours of dosing lung lavage and 2) whether residual neutralizing antibody in animals with 10 m a g RSHZ19 intraperitoneally, significant lung lavage fluids could be detected.
concentrations of human antibody were detected in the plasma Histologic studies. Lungs designated for histologic studies and in lavage fluids. Maximal concentrations of RSHZ19 were fixed in Omnifix (Zymed Laboratories, Inc., San Fran-occurred in the plasma (approximately 20-40 pglml) 8-72 h cisco, CA) fixative for a minimum of 24 h, embedded in low after dosing, and peak lavage concentrations (0.4-0.7 pglml, 3 melting point paraffin and sectioned at 5 pm thickness. Sec-ml total) were observed 24-72 h post-dose. At 1 wk (168 h), tions were then stained with hematoxylin and eosin, coded, and the plasma concentrations were about half-maximal, and the observed (in a blinded fashion) for perivascular and peribron-lung lavage concentrations of mb were approximately twochial infiltrates, septa1 thickening, and the presence of inflam-thirds of the maximum levels. In general, the amount of matory cells in the alveoli. Ten consecutive microscopic fields on each section were observed using the 40X objective and an up, over, and down pattern. For each of the four characteristics, a value of 0 to 3 was assigned, with 0 = not evident; 1 = evident in 1 to 3 of the fields observed; 2 = evident in 4 to 6 fields observed, and 3 = evident in >6 of the observed fields. Total scores were obtained by adding scores for each of the four characteristics noted above (the maximum score for an individual animal would be 12).
Statistics. The Newman-Keuls multiple comparison test and Kruskal-Wallis analysis of variance were used to compare geometric mean titers in different groups. Sera with undetectable neutralizing titers or lung fluid samples with undetectable virus titers were assigned a value of 0.5 or 0.8, respectively, for statistical evaluation. These tests and the determination of all descriptive statistics (i.e. geometric mean titers and SD) were RSHZ19 in the lung lavage was estimated to be 1% of the amount in plasma. The electrophoretic integrity of the RSHZ19 MAb in lung lavage was confirmed by Western blot analysis (data not shown). Lung lavage and plasma concentration time curves after intramuscular administration were similar up to 168 h (7 d, not shown). These studies thus confirmed that MAb levels remained relatively constant for the duration of virus shedding (i.e. d 1-6 postchallenge).
Pulmonary RSV and serum virus neutralization titers after prophylactic or therapeutic administration of RSHZl9. Mean pulmonary RSV and virus-neutralizing serum titers measured in cotton rats in which RSHZ19 was administered i.p. 24 h before challenge with subgroup A or B RSV strains are shown in Table 2 . The virus titers and serum neutralizing titers were determined on d 4 postchallenge. In all experiments, the reductions in pulmonary virus titers seen were directly proportional to the dose of RSHZ19 MAb administered and to the levels of virus-neutralizing antibody in the serum at the time of sacrifice. At the 10 mglkg dose, lung virus was undetectable in both the A and B challenge groups, indicating clearance of at least 2.3 10g,~/g lung, which corresponded to serum neutralization titers of 1:32. In one prophylaxis study (for which histology results are shown later in Table 4 ), a parallel group of animals were also sacrificed on d 7 postinfection, and no lung virus was detected in control or RSHZ19-treated animals, indicating the infection had resolved as expected (data not shown).
The mean pulmonary RSV titers and circulating anti RSVneutralizing titers seen in cotton rats given RSHZ19 or control MAb CMHZOO 4 d after challenge with either subtype A or B RSV are also shown in Table 2 . Animals were killed 24 h after antibody treatment (i.e. on d 5 postinfection).
Significant reductions in pulmonary RSV titers occurred in groups of cotton rats given 2 1 mglkg RSHZ19 MAb. Doseresponse curves for animals challenged with either type A or B virus were overlapping, showing that protection versus subgroup A or B strains was equivalent when MAb was administered therapeutically. [Power calculations of the dose re- Fig 1) . Minimum serum levels of approximately 3.3 pg/ml were required for significant lung virus reduction, and maximum virus clearance was observed at mean circulating Mab concentrations of 45.6 pg/ml. The serum MAb concentration divided by the corresponding serum neutralizing titer ranged from 0.1 to 1.3 pglml, indicating that the MAb activity in serum was comparable to the in vitro activity of the MAb standard (EC,, = 0.4-3 pg/ml; see Table 1 ). Significant RSV-neutralizing activity was not detected in lung lavage fluid collected from Mab-treated infected or uninfected cotton rats, even when very low doses of virus (3-10 TCID,,) were used in the neutralization assay. Effects of passively administered RSHZ19 MAb on RSV nasal titers. Although significant reductions in pulmonary RSV titers were seen in all experiments conducted in cotton rats inoculated intraperitoneally with RSHZ19 MAb, a significant reduction in mean nasal RSV titers compared to control animals (approximately 1 log,,) was observed in only one of three experiments in which nasal titers were determined (data not shown).
Comparison of prophylaxis with RSHZ19 MAb and HSIg. The protective activity of RSHZ19 for prophylaxis was next compared to a conventional intramuscular formulation of HSIg utilizing the same protocol described above, except that both the MAb and HSIg were administered intramuscularly. As the results in Table 3 show, there was approximately 20-30-fold more circulating human IgG (determined by ELISA) in the cotton rats given the high dose (1000 m a g ) of HSIg than in the animals given 10 m a g of RSHZ19 MAb (0.99-1.4 mg/ml versus 0.05 mg/ml, respectively). Despite the higher levels of circulating human IgG, neutralizing titers in groups administered the high dose of HSIg were equal to (experiment 1) or less than (experiment 2) those in the groups that received RSHZ19 MAb, although virus clearance was clearly not as efficient in animals treated with HSIg even when equivalent circulating neutralizing titers were reached. Pulmonary viral clearance below the level of detection was observed in both experiments in cotton rats treated with 10 m a g RSHZ19, whereas the maximal dose of HSIg (1000 m a g ) resulted in only moderately reduced virus titer (reduction = 1.2 loglo/g lung in experiment 1) or no significant reduction (in experiment 2, in which this HSIg group did not exhibit a significant RSV serum-neutralizing titer). Thus, for HSIg, RSV lung titer correlated inversely with the serum RSV-neutralizing antibody titer and not with serum human IgG concentrations.
Pulmonary histopathology in cotton rats passively administered MAb. Histologic evaluations were made on lungs obtained from cotton rats administered RSHZ19 prophylactically or therapeutically (Table 4) . In these experiments, inflammatory cells were occasionally seen around blood vessels (perivascularly), bronchi and bronchioles, and occasionally within alveoli, in sections of lung taken from normal (i.e. non-virus-infected, untreated) cotton rats ( Fig. 2A) . However, the sections of lung from these animals were generally unremarkable. Indeed, using the scoring system described above, all sections from normal cotton rats had a total score 1 . 0 .
In contrast, numerous foci of inflammatory cells were seen on d 4 and 7 postinfection in the perivascular and peribronchiolar regions of the lung, and in the alveoli, in lung sections from virus-infected cotton rats given placebo (PBS), irrelevant MAb (CMHZOO), or <1 m a g RSHZ19 (Fig. 2 , B through D, and Table 4 ). The frequency of these observations was reflected by total histopathology scores for these sections ranging from 8 to 10.
Intermediate total histopathology scores ranging from 3 to 7 were recorded for cotton rats given >1 to 3.3 mg RSHZ19lkg. Total scores comparable to background values (0 to 1) occurred in sections of lung from RSV-infected animals given the highest doses (5-10 m a g ) of RSHZ19, although virus titrations in parallel groups of animals detected low levels of residual virus (approximately 1 log,,, see Table 2 ) in these groups. .In no instance was there any evidence of exacerbated pulmonary disease in cotton rats administered MAb (i.e. total histopathology scores were never greater for animals given virus and MAb than for virus-infected animals given either PBS placebo or control MAb CMHZOO).
DISCUSSION
A major aim of these studies was to determine the in vivo efficacy of RSHZ19 MAb against virus strains belonging to both the A and B subgroups of RSV. In in vitro microneutralization assays, RSHZ19 was active against RSV strains belonging to both major subgroups as indicated by the consistently low EC,, values (Table 1 ; 0.4-3 p g proteinlml) obtained against a panel of different subtype A and .B RSV strains. Moreover, therapeutic administration of a single dose of RSHZ19 MAb 4 d after virus challenge consistently resulted in significant protection, regardless of whether the challenge virus was a subtype A (e.g. RSV A2;) or B RSV (e.g. 18537) strain. Sufficient numbers of animals were not used to statistically compare protection between RSV subgroups when the MAb was administered prophylactically; however, the results followed the same trend except that virus (subgroup A or B) was reduced to below detectable levels at the highest MAb dose administered (10 mg/kg). This consistency allowed assignment of an EC,, in cotton rats against RSV of approximately 3.3 mg of proteinlkg, and confirmed the broad spectrum anti-RSV activity of this reshaped human MAb. Although MAb levels in lung lavage were readily detectable by antiidiotype ELISA, neutralization titers could not be detected. This is consistent with the determined MAb concentrations in lung lavage samples (by ELISA; Fig. 1 ) being less than or equal to the MAb EC,, in neutralization assays. Presumably, this represents a dilution effect, and local Mab concentrations were sufficient for effective neutralization as evidenced by reduction in lung virus titers.
A second aim of these studies was to directly compare the protection provided by RSHZ19 with a lot of conventional polyclonal HSIg. Studies by Siber et al. (8) indicated that hyperimmune plasma pools or IgG fractions (1% IgG) with neutralization titers of 1:1859-1:3415 (3-5 pglml), as assayed by microneutralization, represented a 5-fold enrichment over standard i.v. Ig. The neutralization titer of the HSIg used in our experiments was approximately 12.5-25.0 pg/ml IgG, and therefore is similar in titer to standard i.v. Ig preparations as tested by these investigators. As indicated by the data in Table  3 , RSHZ19 was active at markedly lower doses and serum concentrations than standard HSIg when tested in parallel. The reductions seen with the HSIg in the present study were similar to those reported by Prince et al. (6) who showed that intraperitoneal inoculation of 1000 mg/kg i.v. Ig (RSV-neutralizing titer, 1:2905) reduced pulmonary RSV titers only about 1 log,, compared with the control group, despite serum IgG concentrations of 3.7 mglml and serum neutralization titers of 1:59. Notably, prophylactic administration of 500 mg/kg human immune globulin enriched for neutralizing activity against RSV (RSV Ig) resulted in a 2-log reduction in lung virus titer in cotton rats, demonstrating significantly improved potency relative to conventional HSIg (22) . The current studies demonstrate that 10 mglkg RSHZ19 administered prophylactically to cotton rats consistently reduced the virus titers to below detectable levels (22.3 loglo reduction), indicating significantly improved potency compared with either conventional HSIg or to RSVIg. Our results also suggest that higher circulating neutralizing titers may be required for complete clearance of lung virus when the Mab is administered therapeutically versus prophylactically, as had also been reported for HSIg in cotton rats (5) . Previous studies with HSIg in cotton rats consistently showed more dramatic effects in reduction of lung virus titers versus viral titers in nasal turbinates (11, 22) , as was the case with RSHZ19 MAb.
The disparity between protective serum RSV neutralizing titers in animals treated with RSHZ19 (rl:32) compared with titers of 1:200-1:400 that have been associated with passive protection by polyclonal immune globulins and RSVIg in cotton rats or in infants (8, 10, 11, 22) , may be due to the homogeneity of the RSHZ19 MAb, compared with the heterogeneity of the HSIg preparation where only a subset of the neutralizing antibodies present may actually be protective. For example, an analysis of F protein-specific MAb indicated that FI activity is the most reliable indicator of in vivo protection (15) , although only a subset of those MAb that are neutralizing also have fusion-inhibiting activity (15, 23) . Thus, in addition to reduced antiviral potency based on a comparison of neutralization titers (approximately 12-25-fold) or fusion inhibition titers (approximately 65-130-fold), the ratio of neutralizing to fusion-inhibiting activity of the RSHZ19 MAb versus the lot of HSIg used in the current study (1.0 versus 5.0, respectively) may also contribute to the relative difference in potency observed. Exacerbation of RSV disease has been associated with attempts to induce active immunity to RSV, but not passive immunity in studies utilizing polyclonal Ig (5) (reviewed in Ref. 11). However, because RSHZ19 is directed to a single F protein epitope, the capacity of this MAb to induce pulmonary histopathology could not be predicted based on previous studies. For this reason, a determined effort was made to compare the pulmonary histopathology seen in MAb-treated, RSVinfected animals with that seen in virus-infected, untreated control animals. The results obtained clearly show that the pulmonary histopathology correlated directly with pulmonary virus titers and inversely with both the amount of RSHZ19 MAb administered and the levels of serum anti-RSV titers reached. Under the conditions of the experiments performed, enhanced histopathology did not occur in lungs of any of the cotton rats. It is important to note that only limited time points (d 4 and 7 postinfection) were utilized in these experiments. However, we (24) and others (25) , have induced increased and severe pulmonary immunopathology (i.e. exacerbated disease) in the same timeframe in cotton rats as was studied here by giving formalin-inactivated RSV vaccines prior to intranasal challenge with RSV. Although these results in cotton rats and initial safety studies in normal adults are encouraging (16) , studies in pediatric patients infected with RSV will ultimately be required to determine the safety profile of RSHZ19.
In summary, the protection seen in these studies in cotton rats treated with the RSHZ19 MAb was rapid and often impressive [reductions of pulmonary virus to below detectable levels with the use of modest amounts of antibody (5-10 mglkg)] with no evidence of enhanced disease. The data obtained thus support further clinical development of the RSHZ19 MAb for prophylaxis and therapy of RSV lower respiratory disease in infants and young children.
